Main Takeaway: In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ... Encouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates suggesting ...

Dr Guy Goodwin On Compass Pathways Ptsd Study -

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ... Encouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates suggesting ... This video contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, ...

Important details found

  • In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ...
  • Encouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates suggesting ...
  • This video contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, ...

Why this topic is useful

This format is designed to help readers move from a broad question into more specific pages without losing context.

Sponsored

Frequently Asked Questions

What is this page about?

This page summarizes Dr Guy Goodwin On Compass Pathways Ptsd Study and connects it with related entries, references, and supporting context.

Is the information always complete?

Not always. Some topics may need verification from official or primary sources.

How should readers use this information?

Use it as a starting point, then open related pages for more specific details.

Reference Gallery

Dr Guy Goodwin on COMPASS Pathways' PTSD study
Dr Guy Goodwin on COMP360 Psilocybin Therapy and SSRIs
Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug
Dr Guy Goodwin on COMPASS's trial of COMP360 psilocybin therapy in anorexia nervosa
Can we re-medicalise the psychedelic experience? with Guy Goodwin (Borealis 2025)
Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing
Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!
The Future Directions of Psychedelics: A Conversation With Guy Goodwin, MD
Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine
Compass Pathways CEO on mushroom-based therapy for depression: 'The data was breathtaking'
Sponsored
View Full Details
Dr Guy Goodwin on COMPASS Pathways' PTSD study

Dr Guy Goodwin on COMPASS Pathways' PTSD study

Read more details and related context about Dr Guy Goodwin on COMPASS Pathways' PTSD study.

Dr Guy Goodwin on COMP360 Psilocybin Therapy and SSRIs

Dr Guy Goodwin on COMP360 Psilocybin Therapy and SSRIs

Read more details and related context about Dr Guy Goodwin on COMP360 Psilocybin Therapy and SSRIs.

Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug

Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug

Encouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates suggesting ...

Dr Guy Goodwin on COMPASS's trial of COMP360 psilocybin therapy in anorexia nervosa

Dr Guy Goodwin on COMPASS's trial of COMP360 psilocybin therapy in anorexia nervosa

Read more details and related context about Dr Guy Goodwin on COMPASS's trial of COMP360 psilocybin therapy in anorexia nervosa.

Can we re-medicalise the psychedelic experience? with Guy Goodwin (Borealis 2025)

Can we re-medicalise the psychedelic experience? with Guy Goodwin (Borealis 2025)

Read more details and related context about Can we re-medicalise the psychedelic experience? with Guy Goodwin (Borealis 2025).

Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing

Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing

Read more details and related context about Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing.

Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!

Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!

Read more details and related context about Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!.

The Future Directions of Psychedelics: A Conversation With Guy Goodwin, MD

The Future Directions of Psychedelics: A Conversation With Guy Goodwin, MD

This video contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, ...

Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine

Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ...

Compass Pathways CEO on mushroom-based therapy for depression: 'The data was breathtaking'

Compass Pathways CEO on mushroom-based therapy for depression: 'The data was breathtaking'

Read more details and related context about Compass Pathways CEO on mushroom-based therapy for depression: 'The data was breathtaking'.